Peripheral atherectomy, which is the largest product category within Vascular Intervention, is anticipated to grow 3% to 5%; this compares with previous guidance for growth of 11% to 13%. ❋ Unknown (2010)
Rotational atherectomy uses a tiny rotating tip, covered with thousands of microscopic diamond crystals, to whirr through the plaque. ❋ Elizabeth Ross (1996)
Some studies credit atherectomy with an 85 percent success rate. ❋ Elizabeth Ross (1996)
Supposedly the procedure offers better healing than either traditional angioplasty or directional atherectomy. ❋ Elizabeth Ross (1996)
Directional coronary atherectomy uses a cutting tool mounted on a catheter to shave the plaque off the blood vessel. ❋ Elizabeth Ross (1996)
As we looked at that, there's actually some potential positive benefit around combination of PTA and atherectomy and there is a little bit of a change in reimbursement to kind of bump that in a positive direction.
When using atherectomy, Impella significantly reduced repeat revascularization p=0.02. ❋ Unknown (2010)
*In the atherectomy group, (12%), there was significantly lower repeat revascularization (p=0.04) and higher CK-MB release (p=0.02) in the Impella arm. ❋ Unknown (2010)
Use of atherectomy during PCI has been previously shown to increase CK-MB release ❋ Unknown (2010)
Within Vascular Intervention sales, atherectomy was essentially flat, crossing solutions decreased 2%, and thrombectomy decreased 6%, all compared with the first nine months of 2009. ❋ Unknown (2010)
Vascular Intervention sales declined 6% to $14.6 million and include three product lines: atherectomy (including peripheral and coronary), which decreased 6%, crossing solutions, which was essentially flat, and thrombectomy, which decreased 19%, all compared with the third quarter of 2009. ❋ Unknown (2010)
® PAD System and Diamondback Predator 360° ™ PAD System are percutaneous orbital atherectomy systems indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae. ❋ Unknown (2010)
As a result, our peripheral atherectomy business grew 14% sequentially and 6% year-over-year. ❋ Unknown (2010)
Vascular Intervention sales include three product lines - atherectomy (including peripheral and coronary), which increased 2%, crossing solutions, which decreased 1%, and thrombectomy, which increased 7%, all compared with the first quarter of 2009. ❋ Unknown (2010)
ABMD - News, a leading provider of breakthrough heart support technologies, today announced completion of the PROTECT II study¹ based on a futility determination at the planned interim analysis regarding the primary end-point, which the company views as likely to be due to unanticipated confounding variables related to the use of rotational atherectomy² in the study. ❋ Unknown (2010)
The PROTECT II is a landmark study because it is a first in many categories such as: the complexity and advanced disease of the patient population receiving PCI with hemodynamic support, number of endpoints measured prospectively at 30 days post hemodynamic supported PCI, first use of atherectomy in low ejection fraction EF PCI patients and the first FDA ❋ Unknown (2010)
